A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Eligible age
55–90 yrs
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD. The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Where it's recruiting
Chandler · Phoenix
Anaheim · Canoga Park · Encino · Lancaster …
Apopka · Clermont · Cutler Bay · Delray Beach …
Augusta · Columbus · Decatur
Elgin
Marrero
Rochester Hills
Flowood
Las Vegas
New Hyde Park · Port Jefferson Station
Dayton
Malvern
Source: ClinicalTrials.gov · NCT06126224 · last updated 2026-06-16